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Abstract
Objectives We aimed to investigate whether apparent diffu-
sion coefficients (ADCs) measured by 3.0T diffusion-
weighted magnetic resonance imaging (DWI) associate with
histological aggressiveness of ovarian cancer (OC) or predict
the clinical outcome. This prospective study enrolled 40 pa-
tients with primary OC, treated 2011-2014.
Methods DWI was performed prior to surgery. Two observers
used whole lesion single plane region of interest (WLsp-ROI)
and five small ROIs (S-ROI) to analyze ADCs. Samples from
tumours and metastases were collected during surgery.
Immunohistochemistry and quantitative reverse transcription
polymerase chain reaction (qRT-PCR) were used to measure
the expression of vascular endothelial growth factor (VEGF)
and its receptors.
Results The interobserver reliability of ADC measurements
was excellent for primary tumours ICC 0.912 (WLsp-ROI).
Low ADCs significantly associated with poorly differentiated
OC (WLsp-ROI P = 0.035). In primary tumours, lower ADCs
significantly associated with high Ki-67 (P = 0.001) and low
VEGF (P = 0.001) expression. In metastases, lower ADCs
(WLsp-ROI) significantly correlated with low VEGF recep-
tors mRNA levels. ADCs had predictive value; 3-year overall
survival was poorer in patients with lower ADCs (WLsp-ROI
P = 0.023, S-ROI P = 0.038).
Conclusion Reduced ADCs are associated with histological
severity and worse outcome in OC. ADCs measured with
WLsp-ROI may serve as a prognostic biomarker of OC.
Key Points
• Reduced ADCs correlate with prognostic markers: poor dif-
ferentiation and high Ki-67 expression
• ADCs also significantly correlated with VEGF protein ex-
pression in primary tumours
• Lower ADC values are associated with poorer survival in
ovarian cancer
• Whole lesion single plane-ROI ADCs may be used as a
prognostic biomarker in OC
Keywords Ovarian neoplasms . Neoplasmmetastasis .
Neovascularization pathologic . Cell proliferation . Diffusion
magnetic resonance imaging
Abbreviations
OC Ovarian cancer
DWI Diffusion-weighted magnetic resonance imaging
ROI Regions of interest
* Hanna Sallinen
Hanna.Sallinen@kuh.fi
1 Department of Gynaecology and Obstetrics, Kuopio University
Hospital, Kuopio, Finland
2 Institute of Clinical Medicine, School of Medicine, Gynaecology,
University of Eastern Finland, Kuopio, Finland
3 Department of Clinical Radiology, Kuopio University Hospital,
Kuopio, Finland
4 Department of Biotechnology andMolecularMedicine, A.I. Virtanen
Institute for Molecular Sciences, University of Eastern Finland,
Kuopio, Finland
5 Department of Pathology and Forensic Medicine, Kuopio University
Hospital, Kuopio, Finland
6 Institute of Clinical Medicine, School of Medicine, Pathology and
Forensic Medicine, University of Eastern Finland, Kuopio, Finland
7 Cancer Center of Eastern Finland, University of Eastern Finland,
Kuopio, Finland
8 Institute of Clinical Medicine, School of Medicine, Clinical
Radiology, University of Eastern Finland, Kuopio, Finland
Eur Radiol (2017) 27:4002–4012
DOI 10.1007/s00330-017-4786-z
S-ROI Five small ROIs
WLsp-
ROI
Whole lesion single plane region of interest
ADC Apparent diffusion coefficient
qRT-
PCR
Quantitative reverse transcription polymerase
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VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
CT Computed tomography
FIGO The International Federation of Gynecology and
Obstetrics
WHO The World Health Organization
ICC Interclass correlation coefficient
TR Repetition time
TE Echo time
FFE Fast field echo
SPAIR Spectral attenuated inversion recovery
DWIBS Diffusion-weighted imaging with background
body signal suppression
PPIA Peptidylprolyl isomerase A
OS Overall survival
RFS Recurrence-free survival
IVIM Intravoxel incoherent motion
Introduction
Ovarian cancer is the fifth most frequent cancer among females
and the fourth most common cause for female cancer mortality
[1]. The treatment of ovarian cancer (OC) has developed rap-
idly during the last few decades, but the prognosis remains
poor. Although OC is sensitive to chemotherapy, up to 70%
of patients relapse during the first 3 years after the primary
treatment [1]. Survival in OC is related to age at diagnosis,
stage, histopathological grade and, most of all, size of residual
tumour after sytoreductive surgery [2]. Neoadjuvant chemo-
therapy is an important additional treatment modality in cases
where the tumours are widely spread and optimal surgical result
is not possible without chemotherapy [3].
Molecular pathophysiology of OC is well documented and
various biological markers have been reported to have prog-
nostic significance. Ki-67 is a nuclear protein associated with
cellular proliferation; higher Ki-67 expression in OC is asso-
ciated with more aggressive disease and worse clinical out-
come [4]. Angiogenic growth factors and their receptors pro-
mote and regulate angiogenesis which is essential in tumour
progression. Tumours require neovascularization for growth.
The vascular endothelial growth factor (VEGF) family is the
most studied: VEGFs have mitogenic, angiogenic, and vascu-
lar hyperpermeability effects on tumours [1, 5–8]. VEGF, -B, -
C, and -D signal through three tyrosine kinase receptors:
VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flt-1), and VEGFR-3
(Flt-4) [5].
Diffusion-weighted imaging (DWI) and assessment of ap-
parent diffusion coefficients (ADCs) have recently been intro-
duced as new tools in abdominal imaging and may help to
improve assessment of the metastatic spread of OC at the time
of diagnosis and during follow-up [9–14]. ADCs are affected
by tissue cellularity, fluid viscosity, membrane permeability,
macromolecular structures, and blood flow [15]. Due to high
cellularity, malignancies are associated with lower ADCs [11,
12, 16–19]. However, no standardized measurement protocols
or cut-off values are available for ADC measurements in OC.
The scanner type and size and positioning of regions of inter-
est (ROI), and most importantly b-values have varied between
studies, affecting the differences in ADC values. The purpose
of the present study was to investigate whether ADCs mea-
sured by 3.0T DWI are associated with histological severity in
OC or predict the clinical outcome in patients with OC.
Materials and methods
Patients and study design
This was a prospective single-institution study at Kuopio
University Hospital between 2011 and 2014. The Research
Ethical Committee approved the study protocol. Written in-
formed consent was obtained from all patients prior to enroll-
ment. A total of 40 patients with primary OC (mean age
66 years, range 47-86) treated at Kuopio University Hospital
were included in this study. Patients were followed up until
June 2016. The eligibility criteria were: clinical diagnosis of
primary OC, fallopian tube cancer, or peritoneal carcinoma;
measureable disease at staging computer tomography (CT);
and no contraindication to MRI. Cancer staging was based
on the standards of the International Federation of
Gynecology and Obstetrics (FIGO). Histological type and
grade were evaluated according to the World Health
Organization (WHO) criteria. All patients underwent diagnos-
tic 3.0T MRI before any treatment with a structured protocol
including DWI. Four patients were excluded from imaging
analyses because of severe artifacts: sterilization clip-on (n =
1), motion artifact (n = 2), and hip prosthesis (n = 1) that
strongly degraded the image.
Samples from tumours and metastases for immunohisto-
chemistry and quantitative reverse transcription polymerase
chain reaction (qRT-PCR) analyses were collected during sur-
gery. Five patients receiving neoadjuvant chemotherapy were
excluded from histopathological and qRT-PCR analyses be-
cause chemotherapy causes cellular damage to tumour cells.
The patients received paclitaxel-carboplatin as adjuvant che-
motherapy after an operation, excluding one stage 1A patient
with single carboplatin. Twelve patients received also
bevacizumab either in the primary setting (n = 8) if disease
was stage IIIC-IV and there was residual tumour, or in a
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recurrent situation (n = 4), if they had not received it earlier.
The decision to give bevacizumab for high-risk patients was
based on the protocol that was used in the ICON-7 trial [20].
The patient characteristics are described in Table 1.
Imaging protocol and image analysis
MRI was performedwith a 3.0Tscanner (PhilipsAchieva 3.0T
TX,PhilipsN.V.,Eindhoven,TheNetherlands) and a bodycoil
(Sense-XL-Torso) covering thewhole abdomen from the lower
thorax to the symphysis. The protocol included transaxial, sag-
ittal, and coronal T2-weighted (repetition time (TR) 651 ms,
echo time (TE) 80 ms) and transaxial fat-suppressed spectral
attenuated inversion recovery (SPAIR) and DUAL- fast field
echo (FFE) sequences, and DWI (b-values 0, 300, 600 mm2/s)
and DWI with body signal suppression (diffusion-weighted
imaging with background body single suppression (DWIBS),
b-value 800 mm2/s). A DWIBS sequence was used for visual
detection of tumours. Breath hold was not used in the lower
abdomen DWI_3b sequence, but was used in the upper abdo-
men, where breathing movements are more likely to affect the
image quality. ADCmaps were automatically generated for b-
values of 0, 300 and 600 mm2/s. ADC data was fitted mono-
exponentially byusing these three b-values. Thedetailed imag-
ing protocol is described in Table 2.
Two observers (A.L, S.R, with 2 and 10 years of experi-
ence in gynecological imaging) independently and, blinded to
histological information, evaluated all MRI data using a
Sectra-PACS workstation (IDS7, Version15.1.20.2, Sectra
AB, Linköping, Sweden). ADC values were measured from
the whole lesion covering region of interest (WLsp-ROI) from
the single plane where the tumour appeared largest and five
small subregion ROIs (S-ROI, 1 cm in diameter) that were
drawn both in the primary tumours and in omental cake or
peritoneal lesions (Fig. 1). Cystic and necrotic areas were
meticulously avoided, as they may erroneously increase
ADCs. Small ROIs were placed on the subregions that were
most bright in DWIBS images and had the lowest signal in-
tensity in ADC maps. Throughout the text all ADC values are
quoted with units of x10-3mm2/s.
Immunohistochemistry
Tissue samples were embedded in paraffin and cut into 5-μm-
thick sections. The sections were processed for hematoxylin-
eosin, VEGF (Santa Cruz, 1:250), HIF-1α (Novus 1:75), Ki-
67 (DAKO 1:100), Caspase-3 (Cell Signaling 1:500), CD34
(DAKO 1:500), CD105 (DAKO 1:90), and D2-40 (DAKO
1:200) staining. HIF-1α expression was analyzed in epithelial
OC cells from the nucleus and cytoplasm. VEGF expression
was evaluated in the epithelium and stroma. Ki-67 and
Caspase-3 were analyzed in the nucleus. The percentage of
stained cells was calculated.
The number of microvessels, mean microvessel area (μm2),
microvessel density, and total microvascular area (%) in the tu-
mours were measured from CD34-, CD105-, D2-40- immuno-
stained sections using analySIS software at 200× magnification
in a blinded manner. Three different fields representing
Table 1 Clinicopathological characteristics of patients with ovarian
cancer (N = 40) and themean apparent diffusion coefficient (ADC) values
of the primary tumours in corresponding subgroups of patients
Variable n (%) Mean ADCa P
Ascites 29 (73) 0.820 0.432
No ascites 11 (28) 0.882
BMI > 25 kg/m2 23 (58) 0.803 0.297
BMI ≤ 25 kg/m2 16 (40) 0.900
CA12-5 ≤ 403 21 (53) 0.868 0.350
CA12-5 > 403 19 (48) 0.798
Histological grade 0.035
1 2 (5) 1.232
2 13 (33) 0.864
3 25 (63) 0.784
Stage at diagnosis 0.079
I 5 (13) 0.942
II 2 (5) 1.192
III 17 (43) 0.760
IV 16 (40) 0.852
Histological type 0.637
Serous high grade 28 (70) 0.801
Endometrioid 5 (13) 0.931
Mucinous 2 (5) 1.013
Clear cell 1 (2) 0.783
Other 4 (10) 0.842
Primary residual tumour 0.232
None 16 (40) 0.896
≤1 cm 17 (42.5) 0.817
>1 cm 7 (17.5) 0.753
Chemotherapy response 0.433
Neoadjuvant 5 (12.5)
Complete response 30 (75) 0.857
Partial response 3 (7.5) 0.727
Stable disease
Progressive disease 7 (17.5) 0.802
Tumour recurrence 0.723
No recurrence 22 (55) 0.851
Recurrence 18 (45) 0.802
Patient status
Dead, ovarian cancer 16 (40)
Alive 24 (65)
ADC = apparent diffusion coefficient, BMI = body mass index
aMean value × 10-3 mm2 /s when using the whole lesion single plane
covered region of interest
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maximum microvessel areas were selected from each tumour
[21, 22].Necrotic areaswere avoided.Fivepatientswere exclud-
ed from this analysis due to neoadjuvant chemotherapy.
Quantitative RT-PCR
RNA was isolated using TRI-reagent (Sigma Aldrich). The
cDNAwas synthesized from 5 μg of total RNA using random
hexamer primers (Promega) and RevertAidTM reverse tran-
scriptase (Fermentas) after treating the samples with DNase
(Promega). The expression of mRNAs encoding VEGF,
VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3
was measured according to the manufacturer’s protocol
(StepOnePlus, Applied Biosystems) using specific Assays-
on-Demand target mixes (Applied Biosystems). The expres-
sion levels were normalized to peptidylprolyl isomerase A
(PPIA), and the results are shown as relative expression.
Five patients having neoadjuvant chemotherapy were exclud-
ed from this analysis.
Statistical analysis
SPSS for Windows (Version 22.0, 1989-2013, SPSS Inc.,
Chicago, USA) was used for statistical analyses. ADCs from the
WLsp-ROI and the lowest ADCs from the S-ROIs were used.
Values are presented as mean ± SD unless otherwise stated. An
interclass correlation coefficient (ICC) was used to test interob-
server correlation in continuous variables. The Bland-Altman
method was used to visualize interobserver variability. The
Kruskal-Wallis test and theMannWhitneyU-testwereusedwhen
appropriate. Bivariate correlations for continuous variables were
analyzed using Spearman’s test. Wilcoxon signed rank test was
used to compareADCs, histology, and qRT-PCR results between
primary ovarian lesions and related metastases. For the survival
analyses, ADCs were dichotomized into low and high values
using the median as a cut-off. The Kaplan-Meier method (log-
rank) was used in univariate survival analyses. Significant vari-
ables fromtheunivariateanalyseswereentered inastepwiseman-
ner forCoxregressionmultivariateanalysis.Overall survival (OS)
wasdefinedasthetimeintervalbetweenthedateofsurgeryandthe
date of death or the end of follow-up. Recurrence-free survival
(RFS) was defined as the interval between the date of surgery
and the date of identified recurrence. P < 0.05 was considered
significant, and high statistical significance was set atP < 0.01.
Results
The mean largest diameter of a tumour in the plane where
WLsp-ROI was placed was 77.6 mm (range 23-230 mm).
Table 2 Imaging protocol
Sequence acquisition time Orientation TR
(ms)
TE
(ms)
Flip angle
(°)
FatSat Resolution
(mm)
N slices
(gap mm)
SENSE
factor
Other
Lower abdomen
T2W_TSE 0:41.3 tra Shortest 80 90 - 0.7x0.7x5.0 52 (0.5) 2.0 Breath hold
T2W_TSE 0:35.9 sag Shortest 80 90 - 0.7x0.7x5.0 61 (0.5) 2.0 Breath hold
T2W_TSE 0:33.0 cor Shortest 80 90 - 0.7x0.7x5.0 58 (0.5) 2.0 Breath hold
DWIBS 3:35.7 tra Shortest Shortest - - 1.3x1.3x5.0 62 (0) 2.0 b = 800
DWI_3b 3:40.6 tra Shortest Shortest - STIR 1.8x1.8x5.0 56 (0.5) 2.0 b = 0, 300,
600
dual_FFE 1:13.4 tra 180 1.15 (outphase)
2.30 (inphase)
55 - 1.3x1.3x5.0 56 (0.4) 2.0 Breath hold
Upper abdomen
T2W_TSE 2:24.3 tra Shortest 80 90 - 0.7x0.7x5.0 48 (0.5) 2.0 Navigator
T2W_SPAIR 2:24.0 tra Shortest 70 90 SPAIR
IR = 90 ms
0.7x0.7x5.0 48 (0.5) 2.0 Navigator
DWIBS 3:08.7 tra Shortest Shortest - - 1.3x1.3x5.0 53 (0) 2.0 Navigator
b = 800
DWI_3b 2:21.8 tra Shortest 48 - STIR 1.7x1.7x5.0 48 (0.5) 2.0 Breath hold
b = 0, 300,
600
dual_FFE 1:13.4 tra 180 1.15 (outphase)
2.30 (inphase)
55 - 1.3x1.3x5.0 56 (0.4) 2.0 Breath hold
T1_FS 0:20.2 tra Shortest Shortest 10 SPAIR
IR=shortest
1.5x1.5x3.0 147 (0) 2 Breath hold
TR = repetition time, TE = echo time, FatSat = fat saturation,N slices = number of slices, tra = transversal, sag = sagittal, cor = coronal, TSE = turbo spin
echo, DWIBS = diffusion-weighted imaging with background body signal suppression, SPAIR = spectral attenuated inversion recovery, FFE = fast field
echo, FS = fat saturation, IR = inversion recovery
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The interobserver agreement of the ADC measurements was
excellent for primary tumours (ICC 0.912 for WLsp-ROI,
0.856 for S-ROI). For metastatic lesions (n = 27) the agreement
was good (ICC 0.705 for WLsp-ROI, 0.746 for S-ROI). The
Bland-Altmanmethodwasused tovisualize interobserver repro-
ducibility (Fig. 2) The Bland-Altman 95% limits of agreement
were -0.15 – 0.25 x10-3mm2/s for WLsp-ROI and -0.16 – 0.27
x10-3mm2/s for S-ROI and coefficients of reproducibility were
0.22 and 0.23, respectively. ADCs measured fromWLsp-ROIs
were significantly higher than those measured from S-ROIs.
LowerADCswere associatedwith poorly differentiated histolo-
gy of grade 3 WLsp-ROI P = 0.035, S-ROI P = 0.071 (Fig. 3).
Grade 1 (n = 2) and 2 (n = 13) were pooled together to achieve a
statistically appropriate group size. There were no significant
associations with age, tumour size, FIGO stage, ascites, ca12-5
level, parity, time of menopause, smoking, or obesity.
Histopathological and qRT-PCR analyses
VEGF proteinexpressioninepithelialcellswassignificantlyhigher
in metastases than in related primary lesions (P = 0.008). Ki-67
correlated inversely with VEGF protein expression in primary tu-
mours r= -0.717, p< 0.001. The mean size of lymphatic vessels
(D2-40) was significantly larger in metastases (962.83 μm±
794.24) than in primary lesions (565.36 μm±302.42, P= 0.019).
Therewere no significant differences found in other histopatholog-
ical analyses (HIF-1, Caspase-3, CD-34, CD105,D2-40).
The expression of VEGF-C mRNAwas higher in metastases
(2.63 ± 2.98) than in related primary lesions (0.79 ± 0.56, P =
0.038). VEGF and VEGF-DmRNA levels did not differ signifi-
cantly between primary tumours and metastatic lesions (VEGF:
1.93 ± 3.31 vs. 1.298 ± 1.45, P = 0.859; VEGF-D: 5.38 ± 10.68
vs. 0.51 ± 0.54,P = 0.110). However, in all VEGFRsmRNA ex-
pressionwashigher inmetastases than in relatedprimary tumours
(VEGFR-1: 2.39 ± 2.11 vs. 0.89 ± 0.56, P = 0.021; VEGFR-2:
2.44 ± 3.02 vs. 0.58 ± 0.26, P = 0.008; VEGFR-3: 2.54 ± 2.24
vs. 0.91 ± 0.51,P = 0.011; Fig. 4).
Correlation between ADCs and histology
ADCswere significantly associated with VEGF protein expres-
sion in epithelial cells (WLsp-ROI r = 0.540, P = 0.001; S-ROI
r = 0.552 P = 0.001) and inversely associated with Ki-67 pro-
tein expression in the nucleus (WLsp-ROI r = -0.540, P =
0.001; S-ROI r = -0.507, P = 0.003; Fig. 5), but not with other
histopathologically measured variables in primary tumours. In
metastases, ADCs inversely correlatedwith themean lymphatic
vessel size (WLsp-ROI: r = -0.618, P = 0.043).
Correlation between ADCs and qRT-PCR analyses
In primary tumours, ADCs did not correlate with qRT-PCR
variables. In metastases, ADCs (WLsp-ROI) significantly cor-
related with all VEGFRs mRNA levels (VEGFR-1: r = 0.836,
Fig. 1 Images in a 67-year-old woman with high grade serous ovarian
adenocarcinoma. A large primary tumour was imaged with (a) T2-
weighted, (b) T2 spectral attenuated inversion recovery (SPAIR) fat-
saturated, and (c) diffusion-weighted imaging with background body
signal suppression (DWIBS) (b 800) MRI. * Bright ascites in (a) and
(b). The tumour appears dark in the apparent diffusion coefficient
(ADC) map (d), which illustrates the region of interest placement for
ADC measurements. The whole lesion single plane region of interest
(WLsp-ROI) was placed to cover the whole tumour in the slice in which
the tumour appeared largest. ADC value is 0.695 × 10-3mm2/s. The five
small ROIs (S-ROI) were placed on subregions appearing to have the
lowest signal on the ADC map. Lowest ADC value 0.543 × 10-3mm2/s,
is used in statistical analyses
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P = 0.001; VEGFR-2: r = 0.764, P = 0.006; VEGFR-3: r =
0.627, P = 0.039). ADCs (WLsp-ROI) also significantly cor-
related with VEGF-C mRNA expression (r = 0.855, P =
0.001) but not with VEGF or VEGF-D mRNA expression.
Recurrence-free survival
Thirty-sixpatientswere includedintheanalysisofRFS.Eighteen
patients experienced recurrence during the follow-up. The
medianRFSwas11 ± 6months.ADCsdidnot havea significant
effect onRFS in theKaplan-Meier log rank test. In the univariate
survival analysis, advancedstage,FIGOIII-IV(P = 0.002),pres-
ence of residual tumour in operation (P = 0.008), presence of
ascites (P = 0.036), non-sensitivity to platinum-based chemo-
therapy (P = 0.001), incomplete response to treatment (P =
0.006), and high Ki-67 expression (P = 0.037) were significant
predictors of shorter RFS. None of these variables maintained
their significance in the Coxmultivariate analysis.
Fig. 2 Bland Altman plots show ADC measurements in a whole lesion
single plane region of interest (WLsp-ROI) and a small subregion region
of interest (S-ROI) positioning as performed by the two readers. The
difference in ADC values between two readers (y-axis) is plotted
against the mean ADC of both readers (x-axis). The red line represent
the mean absolute difference (bias) in ADC between the two readers; the
blue lines represent the 95% confidence intervals (1.96 times the standard
deviation) of the mean difference (limits of agreement). The mean
absolute difference in ADC measurements between two readers is
higher when using S-ROI
Fig. 3 Relationship between apparent diffusion coefficients (ADCs) and
the histopathological grade of ovarian cancer. Lower grade cancer was
associated with significantly higher ADCs in the whole lesion covering
region of interest (WLsp-ROI) (A) and in the small subregion regions of
interest (S-ROI) (B) of the primary tumour. Whiskers represent standard
deviation. ADCs measured from the WLsp-ROI were higher than those
measured from the S-ROI (P < 0.001)
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Overall survival
The median follow-up time was 26 months (range 2-63
months, two patients having died two months after diagnosis).
At the end of the follow-up, 16 (40%) patients with OC had
died. The OS of the patients was 26 ± 12 months and the 3-
year OS rate 38% (n = 26). During the 3-year follow-up (n =
26), lower ADCs predicted significantly poorer OS (WLsp-
ROI P = 0.023, S-ROI P = 0.038) when assessing Kaplan-
Meier curves by a log rank test (Fig. 6). In the univariate
survival analysis, lower ADCs, the presence of residual tu-
mour, an incomplete response to treatment, poor response to
chemotherapy, and body mass index (BMI) > 25 kg/m2 were
significant predictors of poorer OS. Bevacizumab treatment
did not have prognostic significance in this patient cohort. In
the Cox multivariate regression analysis, lower ADCs (P =
0.020), an incomplete response to treatment (P = 0.010), and
BMI > 25 kg/m2 (P = 0.031) were independent predictors of
poorer OS (Table 3).
Discussion
We prospectively enrolled 40 patients with OC to study whether
ADCsmeasured by 3.0TDWI imaging associatedwith histolog-
ical severity of OC or predicted the clinical outcome. Our results
illustrate thatmeasurement ofADCs is a valuable tool for charac-
terizing OC. In our cohort, reduced ADCs were associated with
traditional histopathological prognostic markers, such as poorly
differentiated tumours and high Ki-67 expression. ADCs also
significantly correlatedwithVEGFprotein expression inprimary
tumours epithelial cells and with VEGF receptor expression in
metastases. Importantly, lower ADCs predicted significantly
poorer OS at 3 years.
Analysis of ADCs has shown promise in increasing the
precision of diagnosis, prognosis assessment, and predicting
the therapeutic response in different cancers [13, 14, 17, 23],
paralleling the results in preclinical studies [24]. In our cohort,
ADCs measured with WLsp-ROI were lower in poorly differ-
entiated primary tumours, an observation consistent with early
studies [11, 18]. Grade is a significant predictor of OC out-
come [2, 25]. Ki-67 is a nuclear protein associated with cellu-
lar proliferation, and high Ki-67 expression is associated with
more aggressive disease [4]. In primary tumours, ADCs were
inversely associated with Ki-67 protein expression measured
with both WLsp- and S-ROI. Similar results have been pub-
lished for prostate [18] and breast cancer [26].
ADC measurements were extracted from both larger ROIs
covering the entire tumour at a single plane (WLsp-ROI) and
defined subareas within tumours (S-ROI). ADCs measured
from the entire tumour at a single plane were higher than the
values with small subregions. In this cohort, ADC-values
from S-ROIs proved to be inferior to WLsp-ROI in the pre-
diction of OC histopathology and survival. Our results indi-
cate that ADC values measured fromWLsp-ROI are sufficient
to be used as prognostic biomarkers in DWI-MRI of OC. The
correlation of ADC measurements between two readers was
excellent in primary tumours. In Bland-Altman analysis the
95% limits of agreement were slightly wider for S-ROI mea-
surements in comparison to WLsp-ROI measurements
(Fig. 2). The mean ADCs for the primary tumours were lower
in our study than in many earlier studies [27, 28]. However,
there are studies in which the ADCs are consistent with our
results [11, 12, 16]. Conflicting ADCs in the literature could
be caused by differences in ROI placement, scanners, diffu-
sion gradients, the b values used and fitting of ADC data.
Interestingly, we observed a significant correlation
between the ADCs measured with WLsp-ROI and 3-
Fig. 4 Differences in vascular
endothelial growth factor C
(VEGF-C) and VEGF receptors
(VEGFR) mRNA levels in
metastases and primary tumours
(n = 35). VEGF-C (P = 0.038)
and VEGFR-1 (P = 0.021),
VEGFR-2 (P = 0.008), and
VEGFR-3 (P = 0.011) relative
expressions were higher in
metastases (M) than in related
primary lesions (P) according to
quantitative reverse transcription
polymerase chain reaction
(qRT-PCR) analyses. Box-plots
represent mean and whiskers
standard deviation. The
expression levels were
normalized to peptidylprolyl
isomerase A (PPIA)
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year OS in Cox regression analysis. However, there was
no difference in 1- or 2-year survival. ADCs did not
correlate with recurrence-free survival. There are no pre-
vious reports on the significance of ADC in the
prediction of OC, but in cervical cancer lower ADCs
significantly associate with worse survival [29].
In our cohort, higher ADCs were associated with high
VEGF protein expression in endothelial cells. Previously, it
Fig. 5 Histological samples of
ovarian cancer tumours at 20x
magnification and connection to
apparent diffusion coefficients
(ADCs). a Staining of vascular
endothelial growth factor (VEGF)
in epithelial cells with high and
low expression. Scatter-dot graph
illustrates the correlation between
ADC when the ADC was
measured using the whole lesion
single plane region of interest
(WLsp-ROI) and VEGF
expression. b Ki-67 staining of
the nucleus in high grade serous
adenocarcinoma with high and
low expression. Scatter-dot graph
illustrates the correlation between
ADC when the ADC was
measured using the WLsp-ROI
and Ki-67 expression
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has been shown that VEGF expression is high already in the
early stage of disease; it is not growing exponentially when
the tumour grows [30]. This could be a reason for the positive
correlation between VEGF and ADC in our study. One previ-
ous study had shown that VEGF expression determined al-
ready in the early stage of disease showed prognostic value
[31]. In a study of colorectal cancer, increased VEGF expres-
sion was associated with well-differentiated tumours [32].
VEGF expressionhasbeenshown tobehigher inmetastases
than in primary tumours [33]. This is in line with our results; in
this study VEGF protein expression was higher in metastases.
Thepresent studyalsoshows thatVEGF-C,VEGFR-1, -2,and-
3 mRNA expression is higher in metastases than in related pri-
mary tumours. Inapreviousstudy, levelsofVEGF-C,VEGF-D
and VEGFR-3 proteins significantly increased in the presence
of peritoneal metastases of OC outside the pelvis [34]. The
presence of more mRNAs for angiogenic factors and their re-
ceptors may be expected when there is a need for accelerated
neovascularization atmetastatic sites.VEGF-Cand its receptor
VEGFR-3 are mediators of lymphangiogenesis [7], and higher
expression in metastatic lesions compared to primary tumours
reveals the possible role of lymphangiogenesis in metastatic
tumour spread.
The strengthof thepresent study is theprospectively collect-
ed OC cohort with DWI-MRI and multiple histopathological
and angiogenesis markers analysed immunohistochemically
and with qRT-PCR. Interobserver correlations of the analyses
used were substantial. However, there are no consistent guide-
lines for DWI-MR imaging of patients with OC. The imaging
protocol of the present study generatedADCmaps from three b
values (including b = 0). Intravoxel incoherent motion (IVIM)
is an imaging technique that makes separate estimations of tis-
sue perfusion and diffusivity using multi-b-value DWI.
Recently, implementation of IVIMwithDWI has been studied,
for example, in patients with cervical cancer [35] and breast
cancer [36] andhas shownpromise in improving the specificity
of MRI. Unfortunately, our imaging protocol did not contain
IVIM parameters. Additional limitations were the small study
population and heterogeneous histological types of epithelial
OC. However, in clinical situations, the cancer histology is not
knownpre-operatively, and itwouldbeverybeneficial ifADCs
were useful in all histological types. We had to exclude four
patients due to technical reasons in DWI-MRI and five from
histological and qRT-PCRanalyses due to neoadjuvant chemo-
therapy, which may have affected our results.
DWI, which is easily incorporated into standard MRI pro-
tocols, is a new promising tool for the diagnosis and follow-up
of OC patients. In our cohort, there was a correlation between
ADCs and histopathological prognostic markers and outcome.
Our results indicate that WLsp-ROI can reproducibly be used
tomeasure ADC values, and that it can be used as a prognostic
biomarker in OC. Larger scale studies are needed to confirm
Table 3 Univariate and
multivariate analysis of 3-year
overall survival
Variable Univariate analysis Multivariate analysis
P Hazard ratio 95% CI P
ADC for WLsp-ROI 0.023 10.204 (1.404-74.154) 0.020
Primary residual tumour (cut-off 1 cm) 0.007 0.497 (0.085-2.891) n.s.
Response to treatment <0.001
complete response 0.760 (0.031-18.674) 0.008
partial response n.s.
progressive disease 14.564 (1.912-110.950) 0.010
Platina sensitive <0.001 . n.s.
BMI (cut-off 25 kg/m2) 0.002 9.920 (1.200-81.950) 0.031
ADC = apparent diffusion coefficient, BMI = body mass index, CI = confidence interval, WLsp-ROI = whole
lesion single plane covered region of interest, n.s. = not significant
Fig. 6 Univariate analysis of cumulative overall survival in relation to
dichotomized apparent diffusion coefficients (ADCs). The 3-year overall
survival was significantly prolonged in patients with high ADCs mea-
sured using the whole lesion single plane covered region of interest
(WLsp-ROI)
4010 Eur Radiol (2017) 27:4002–4012
our observations and to clarify the prognostic value of DWI in
patients with OC.
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